Dr. Sudipto Mukherjee, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 74
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MI license 4301089624
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Akron General Medical Center Akron, OH
- Cleveland Clinic Avon Hospital Avon, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 74
- Services billed
- 341
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 92 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 75 | 41 |
| Telephone medical discussion with physician, 21-30 minutes | 59 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 46 |
| Bosulif (bosutinib) | 32 |
| Sprycel (dasatinib) | 28 |
| Acyclovir Other prescribers in Royal Oak, MI | 27 |
| Venclexta (venetoclax) | 24 |
| Ayvakit (avapritinib) | 22 |
| Levofloxacin Other prescribers in Royal Oak, MI | 17 |
| Pantoprazole Sodium Other prescribers in Royal Oak, MI | 17 |
| Jakafi (ruxolitinib phosphate) | 15 |
| Pegasys (peginterferon alfa-2a) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $23,930 in total to this clinician.
| Recordati_rare_diseases_inc. | $13,112 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $5,730 |
| Sobi, Inc | $5,088 |
| Consulting Fee | $20,190 |
|---|---|
| Honoraria | $3,740 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Recordati_rare_diseases_inc. Jan 23, 2025 | Consulting Fee SYLVANT · ONCOLOGIC AGENT | $9,372 |
| E.r. Squibb & Sons, L.l.c. Oct 6, 2025 | Consulting Fee | $5,730 |
| Sobi, Inc Jun 23, 2025 | Consulting Fee Gamifant · Hematology | $5,088 |
| Recordati_rare_diseases_inc. Apr 30, 2025 | Honoraria SYLVANT · ONCOLOGIC AGENT | $3,740 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $18,783 in research payments for these studies, mostly to the institutions running them.
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT02467270
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.